Sponsored Research (Details) - USD ($) $ in Thousands		12 Months Ended
	Feb. 01, 2021	Dec. 31, 2023	Dec. 31, 2022
Sponsored Research (Details) [Line Items]
Research expenses		$ 901	$ 3,047
CRADA Agreement [Member]
Sponsored Research (Details) [Line Items]
Research expenses		46	100
CHOP Agreement [Member]
Sponsored Research (Details) [Line Items]
Research expenses		$ 13	$ 159
Harvard University’s Brigham and Women’s Hospital [Member]
Sponsored Research (Details) [Line Items]
Description of debt instrument, frequency of periodic payment		The Company is responsible for payments up to $849 related to the agreement, half of which was paid upon contract execution during the second quarter of 2022. Remaining payments are due as follows: (i) 20% upon the enrollment of the first patient, (ii) 20% upon the enrollment of the final patient and (iii) 10% upon lab receipt of shipments for all initially planned assays. In addition to the $424 payment upon execution, the Company incurred $272 of other costs related to VECTOR. Costs associated with the clinical trial agreement are being recorded as research and development expenses in the consolidated statements of operations.
U.S. Department of Health and Human Services [Member] | CRADA Agreement [Member]
Sponsored Research (Details) [Line Items]
Fund amount		$ 200
Children’s Hospital of Philadelphia [Member] | CHOP Agreement [Member]
Sponsored Research (Details) [Line Items]
Fund amount	$ 311